Drug Profile
Research programme: G protein-coupled receptor modulators - EPIX/GlaxoSmithKline
Alternative Names: GPCR modulators - EPIX/GlaxoSmithKline; GPCR-targeted therapeutics - EPIX/GlaxoSmithKlineLatest Information Update: 16 Oct 2009
Price :
$50
*
At a glance
- Originator EPIX Pharmaceuticals
- Class
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued CNS disorders
Most Recent Events
- 05 Jun 2008 EPIX Pharmaceuticals achieves milestone by identifying three lead candidates for optimisation in the third GPCR discovery programme in collaboration with GlaxoSmithKline
- 06 Nov 2007 EPIX Pharmaceuticals achieves milestone by identifying three lead candidates for optimisation in the second GPCR discovery programme in collaboration with GlaxoSmithKline
- 15 Aug 2007 EPIX achieves milestone by identifying three lead candidates for optimisation in the first GPCR discovery programme